Study of samuraciclib plus chemo for basal-like pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new drug, samuraciclib, combined with standard chemotherapy (gemcitabine and nab-paclitaxel) for people with a specific type of advanced pancreatic cancer called basal-like. The goal is to see if this combination works better than chemo alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have metastatic pancreatic cancer that is the basal-like subtype (confirmed by a special test).
- You have not had chemotherapy for metastatic disease before, or you finished previous treatment more than 6 months ago.
- You are able to take pills by mouth.
- You have adequate kidney, liver, and bone marrow function.
- You have not had a heart attack, stroke, or blood clot in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.
This trial tests a new drug called samuraciclib in people with a specific type of pancreatic cancer that can be removed with surgery or is confined to the pancreas. The drug may help stop the cancer from growing, and this study aims to see if it is safe and effective before surgery.
This trial tests a combination of three drugs (gemcitabine, erlotinib, and nab-paclitaxel) for people with a specific type of pancreatic cancer called 'basal-like' PDAC. It aims to see if this targeted approach works better than standard treatment.
This trial tests adding surufatinib (a targeted therapy) to standard chemotherapy (gemcitabine and nab-paclitaxel) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if the combination helps shrink or control the tumor better.
This trial tests a combination of four drugs (surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine) as a first treatment for people whose pancreatic cancer has spread to other parts of the body. The goal is to see if this combination helps shrink tumors and improve survival.
This trial tests a new combination of drugs (chiauranib, a PD-1 inhibitor, and two chemotherapy drugs) for people with a specific type of advanced pancreatic cancer who have not had prior treatment. It aims to see if this combination can help shrink tumors and improve outcomes.
Hear when a new Pancreas Cancer, Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.